SAHPRA Expedited Review Pathways: Accelerating Novel HIV Therapy Access in 2025

Key Takeaways

• Seven-month approval timeline: SAHPRA approved lenacapavir in October 2025, seven months after Gilead's March 2025 submission, using the EU-M4all procedure to accept EMA-approved manufacturing and quality data (SAnews).
• First-in-class mechanism: Lenacapavir, a capsid inhibitor, binds HIV capsid proteins to disrupt viral replication at multiple stages, offering a new option for treatment-experienced patients with multidrug-resistant HIV-1.
• CAPELLA trial efficacy: In the phase 2/3 study (NCT04150068), 87.5% of lenacapavir recipients achieved meaningful viral load decrease versus 16.7% on placebo during functional monotherapy (EMA EPAR).
• Biannual dosing advantage: After oral initiation on days 1, 2, and 8, patients receive subcutaneous injections every 26 weeks—addressing adherence challenges with daily oral regimens.

What Is Lenacapavir and How Does It Work?

Lenacapavir is a first-in-class HIV capsid inhibitor that targets the conical protein shell surrounding HIV's genetic material. By binding to capsid proteins, the drug interferes with multiple steps essential for viral replication—viral entry, assembly, and release. This multimodal mechanism distinguishes lenacapavir from existing antiretroviral classes.

The drug is available as Sunlenca tablets and injection. Patients begin with oral tablets on days 1, 2, and 8. One week after the day-8 dose, they transition to subcutaneous injections administered every 26 weeks. This long-acting formulation maintains therapeutic concentrations for six months, reducing dosing burden compared with daily oral regimens.

The U.S. Food and Drug Administration approved lenacapavir in December 2022 for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current regimen due to resistance, intolerance, or safety considerations. The European Medicines Agency followed in 2022 via centralized authorization.

How Did SAHPRA Review Lenacapavir So Quickly?

SAHPRA's seven-month review timeline reflects strategic use of the EU-M4all (European Medicines for All) procedure. This pathway enables regulatory authorities outside the European Union to rely on EMA-approved quality and manufacturing documentation rather than conducting duplicate assessments. According to SAHPRA, the procedure strengthens regulatory systems and accelerates access to essential medicines.

Gilead submitted the lenacapavir application to SAHPRA in March 2025. The regulatory authority completed its assessment by October 2025, making South Africa the first African country to register the drug. This timeline compares favorably with standard regulatory reviews, which often extend 12 months or longer for novel molecules.

The EU-M4all procedure does not shortcut clinical evaluation. SAHPRA maintained rigorous standards by focusing its assessment on clinical efficacy and safety data while accepting EMA-verified chemistry, manufacturing, and controls (CMC) documentation. This risk-proportionate approach allocates regulatory resources efficiently without compromising patient safety.

Regulatory Milestone	Date	Source
FDA Approval (U.S.)	December 22, 2022	FDA Approval Letter
EMA Authorization (EU)	2022	EMA EPAR
SAHPRA Submission (South Africa)	March 2025	SAnews
SAHPRA Approval (South Africa)	October 2025	SAnews

What Evidence Supports Lenacapavir's Efficacy?

The CAPELLA study (NCT04150068) provided the primary clinical evidence for lenacapavir's regulatory approvals globally. This phase 2/3 trial enrolled heavily treatment-experienced adults living with HIV-1 who had multidrug resistance and were failing their current antiretroviral regimen.

The study design included a functional monotherapy period. Participants with HIV-1 RNA ≥400 copies/mL and minimal viral decline were randomized to receive either lenacapavir or placebo as an add-on to their failing regimen for 14 days. This approach isolated lenacapavir's antiviral activity.

Results were striking. During the functional monotherapy period, 87.5% (21 of 24) of lenacapavir recipients achieved a meaningful decrease in viral load. In contrast, only 16.7% (2 of 12) of placebo recipients showed similar response. Following the blinded period, placebo recipients crossed over to lenacapavir.

The maintenance phase evaluated long-term efficacy with subcutaneous lenacapavir 927 mg administered every 26 weeks alongside an optimized background regimen. Participants have the option to continue receiving injections until commercial access becomes available in their country or the study concludes.

Why Is This Approval Significant for South Africa?

South Africa carries one of the world's largest HIV burdens. According to UNAIDS data, approximately 8.45 million people are living with HIV in the country. Access to novel therapies with new mechanisms matters profoundly for treatment-experienced patients who have exhausted standard options.

Multidrug-resistant HIV-1 poses a particular challenge. When viruses develop resistance to multiple antiretroviral classes, treatment options narrow. Lenacapavir's unique capsid inhibition mechanism provides a functional salvage option for these patients. The biannual injection schedule further addresses adherence barriers that contribute to treatment failure.

Beyond individual patient impact, SAHPRA's rapid approval signals South Africa's commitment to timely access for innovative medicines. The seven-month timeline demonstrates that regulatory efficiency and scientific rigor are not mutually exclusive. This precedent may encourage sponsors to bring other high-priority therapies to South Africa.

What Comes Next for Lenacapavir Access?

Approval is a milestone; access is the goal. South African Health Minister Dr. Aaron Motsoaledi announced plans to integrate lenacapavir into domestic financing mechanisms at a national roundtable in October 2025. The government aims to launch the drug as early as March 2026, with routine funding targeted within two years.

Gilead has committed to tiered pricing for resource-limited settings. Multiple manufacturers, including facilities in Egypt, are expected to produce the drug at $40 per person per year under voluntary licensing agreements. This pricing structure could facilitate broader access across the African continent.

For patients, the path to treatment involves several steps. Prescribing requires physicians experienced in HIV management. Patients must commit to the injection schedule—missed doses risk viral rebound and resistance development. If lenacapavir therapy stops, patients must transition immediately to alternative suppressive regimens.

Frequently Asked Questions

Primary Sources

1. U.S. Food and Drug Administration. Approval Package for Sunlenca (lenacapavir). NDA 215973/215974. December 22, 2022.
2. European Medicines Agency. Sunlenca: EPAR - Medicine Overview. Updated 2022.
3. South African Government News Agency. SA becomes first African country to register groundbreaking anti-HIV injection lenacapavir. October 27, 2025.
4. ClinicalTrials.gov. Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen: CAPELLA Trial. NCT04150068. Registered November 21, 2019.
5. UNAIDS. South Africa HIV Data. Accessed 2025.